Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Date:12/9/2008

roperties will provide improved efficacy and reduced incidence of bleeding in patients in the Phase II program."

Advancing Patient Care

PRT060128 is the only reversible, direct acting, IV and oral ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes that PRT060128 may provide significant benefits over other anti-platelet agents through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable platelet inhibition in the chronic setting. Additionally, due to its reversible binding to the platelet P2Y12 ADP receptor, PRT060128 may offer a favorable bleeding profile compared to thienopyridines, such as clopidogrel and prasugrel, which irreversibly bind to platelets. In Portola's clinical studies to date with the IV and oral formulations of PRT060128, results showed that PRT060128 appeared to be well-tolerated without serious adverse events and demonstrated predictable, dose-dependent platelet inhibition.

INNOVATE-PCI is designed to provide important safety, tolerability and efficacy information for further studies that Portola may conduct in acute coronary syndromes, secondary prevention of ischemic events, and elective PCI.

About Thrombosis

Thrombosis, or the development of harmful blood clots within the arteries or the veins, obstructs the flow of blood through the circulatory system and can lead to serious complications or death if it is not recognized or treated effectively. Despite advances, there remains a significant unmet need in preventing, diagnosing and treating thrombosis, which is currently responsible for 22% or 13 million of all global deaths, estimated by the World Health Organization. Arterial clots are the major cause of heart attack and stroke while venous clots can cause deep-vein th
'/>"/>

SOURCE Portola Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
2. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
3. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
8. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
9. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
10. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
11. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... --A Harvard medical expert internationally recognized as a ... Tour,s decision last month to suspend Doug Barron ... as having the medical condition hypogonadism ... "unreasonable, unfair and discriminatory." ,, Hypogonadism ... levels, often referred to informally as Low ...
(Date:12/15/2009)... 15 Fenwal Inc., a global medical ... safety and availability, announced today that the U.S. ... to market InterSol ® platelet additive solution. ... is a specialized product used in combination with ... blood component used to prevent or treat bleeding. ...
(Date:12/15/2009)... 15 Reportlinker.com announces that a ... its catalogue: ,, Boehringer Ingelheim GmbH: ... ,, Introduction ,, This analysis ... Boehringer Ingelheim in the Rx pharmaceutical sector. ... pipeline analysis and assessment of financial performance, ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Marine biomedicine researchers decode structure of promising sea compound 9730 1Marine biomedicine researchers decode structure of promising sea compound 9730 2Childrens Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 55631 1Childrens Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 55631 2Childrens Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 55631 3Scans Shed New Light on Concussions 55629 1Scans Shed New Light on Concussions 55629 2
... and Reported Today ... Study Completed, HAMBURG, Germany and OXFORD, England, March ... to announce the,preliminary findings of a double-blind, single-dose, 3-way ... receptor antagonist, EVT,101. The study was performed in 19 ...
... In the medical,community at large, there is no ... in the heart muscle. Multiple attempts by medical,research scientists ... repair,itself after an individual suffers a heart attack have ... Critical Care Medicine, located in Rancho Mirage,California, is home ...
Other Medicine Technology:Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks 2Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks 3Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack 2
(Date:12/15/2009)... The U.S. Senate today rejected an amendment ... that would have helped make prescription drugs more ... importation of lower priced drugs from abroad. The ... Senators Dorgan, Snowe, McCain, Grassley and Stabenow, would ... the skyrocketing costs of prescription drugs. ,, The ...
(Date:12/15/2009)... NAPA, Calif., Dec. 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences ... healthy aging, today announced that shareholders had approved all three resolutions that the Company had ... were as follows: , , Description of ... Votes ... For ...
(Date:12/15/2009)... SUNNYVALE, Calif., Dec. 15 Palo Alto ... Shinshu University has deployed its PA-4000 Series next-generation ... network and for enhanced visibility and control over ... University is a Japanese national university with eight ... in 1949 by integrating a number of academic ...
(Date:12/15/2009)... to the Lupus Foundation of America and the Saint ... Julian Lennon, son of the legendary John ... digital single, "LUCY," to raise funds for research on ... 100 percent of the proceeds from downloading "LUCY" at ... America (LFA), and the Saint Thomas, Lupus Trust in ...
(Date:12/15/2009)... 15 Vitech Systems Group, a leading ... (CRM) software, announced today that it has completed ... the Screen Actors Guild-Producers Pension & Health Plans ... service capabilities to SAG-PH call center personnel in ... installed using Vitech,s V3 Benefits Administration System which ...
Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2
... in Significantly Lower Infection ... ... about the,rising incidence of methicillin-resistant Staphylococcus aureus (MRSA),infections have prompted lawmakers ... take more aggressive steps to prevent its spread.,Three states have passed ...
... today,at the Society of Interventional Radiology,s 33rd Annual ... metro area, only 18 percent of the,women who ... uterine,fibroid embolization (UFE), a minimally invasive treatment for ... safe, effective,established treatment that has been widely available ...
... 18 NHS Choices ( http://www.nhs.uk ), the,digital ... Autism package aimed to,help people learn more about ... on NHS accredited information, the features (, http://www.nhs.uk/Livewell/Autism/Pages/Autismhome.aspx ... and provides them with clinically approved,guidance to help ...
... Greenhill & Co., Inc.,(NYSE: GHL ), a ... will join the Firm as a Managing Director. Mr.,Giaquinto, ... Health Care,Group at Citigroup Global Markets, will focus on ... spent 18 years covering health care companies as an,investment ...
... white matter levels may assist early identification of walking problems ... age-related changes to white matter in the brain affects how ... their balance, a new study says. , White matter changes ... The study participants included 639 women and men, ages 65 ...
... market will see a compound annual growth, rate of ... Group, WALTHAM, Mass., March 18 According to ... report, which covers markets in the US, Europe, and ... grow from a value,of just under $60 million in ...
Other Medicine News:Health News:More States Move to Require Hospitals to Screen Patients for MRSA 2Health News:More States Move to Require Hospitals to Screen Patients for MRSA 3Health News:More States Move to Require Hospitals to Screen Patients for MRSA 4Health News:Few Women Hear About Uterine Fibroid Embolization Treatment Option Directly From Gynecologists 2Health News:Few Women Hear About Uterine Fibroid Embolization Treatment Option Directly From Gynecologists 3Health News:Few Women Hear About Uterine Fibroid Embolization Treatment Option Directly From Gynecologists 4Health News:Balance in Old Age Tied to Brain Changes 2Health News:Global Cervical Artificial Disc Market to Hit $1 Billion by 2012 2
... higher magnification for advanced surgical procedures. Prismatic ... at the highest magnification. 3.5x, 4.5x and ... color rendition is ideal for surgical applications. ... produce a superior image. The compact abd ...
... The XL Advantage delivers higher magnification ... a crisp, true image, even at the ... to edge clarity and precise color rendition ... treated with an anti-reflective coating produce a ...
... Made up of doublet objective and high ... 2.5x and 3.0x. The true benefit of ... whilst maintaining focal clarity is made possible ... The ultra lightweight aluminum bar and individual ...
... Galilean loupes are ideal for general ... magnification and a large field of ... laser aligned, lightweight and comfortable to ... distance and superior depth of focus ...
Medicine Products: